Background {#Sec1}
==========

γδ T cells are minor subset, 1--5%, among circulating T cells, but are present in abundance within mucosal lymphoid tissue, therein comprising as much as 50% of T cells. The two main subsets are Vδ1 and Vδ2 T cells \[[@CR1]\]. The Vδ1^+^ γδ T cells are mainly situated at mucosal sites and respond to non-classical major histocompatibility complex molecules such as MICA and/or MICB expressed on stressed cells \[[@CR2]\]. The Vγ9Vδ2 T cell subset on the other hand are dominant in the peripheral circulation and respond to phospholigands (non-peptide molecules) derived from potentially diverse microbes, including mycobacteria \[[@CR3]\]. A role for Vγ9Vδ2 cells in anti-microbial immune defense is suggested by an increase in the activation and proliferation of these T-cells in response to intracellular pathogens, such as *Mycobacterium tuberculosis* \[[@CR3], [@CR4]\].

In vitro, Vγ9Vδ2 T cells have been shown to possess diverse immune activities. Vγ9Vδ2 T cells showed activation and expansion upon culture with HIV-infected lymphocytes \[[@CR5]\], and this activation has been associated with direct cytotoxic activity mediated by the Fas/Fas-L interactions and by cytotoxic granules. Indirect anti-microbial activities of Vγ9Vδ2 T lymphocytes include roles in Th1 T-cell polarization and dendritic cell (DC) maturation \[[@CR6]\].

Prior studies have demonstrated a reduced expression of CD28 and an increased expression of CD38 and HLA- DR on γδ T cell populations of HIV patients, findings also seen with conventional α/β T cells, suggesting the possibility that all circulating T lymphocyte share similar phenotypic abnormalities in HIV infected patients \[[@CR7]\]. Similarly, HIV infected patients were shown to have an increased level of Vδ1 \[[@CR8], [@CR9]\] and a decreased level of Vδ2 cells \[[@CR9]--[@CR11]\]. Although there has been no clear conclusion, the increased Vδ1 T cell subset may have been due to redistribution from mucosal areas as a result of changes in cytokine levels \[[@CR6]\] rather than HIV antigen driven expansion \[[@CR8], [@CR12]\]. Notably, the reduction in the proportion and function of the Vδ2 subset was marked in patients with advanced AIDS stage, and this partially recovered after active antiretroviral therapy (ART) \[[@CR10], [@CR11]\].

There are conflicting data on the frequency or functional response of total γδ and Vδ2 T cells in pulmonary TB patients. Some studies have reported an increase in frequency and function of γδ T cells and Vδ2 subsets in TB patients \[[@CR13]\]*,* while others reported a decrease in Vδ2 subsets frequency and function following whole blood stimulation with phosphoantigen \[[@CR14]\]; still others reported no differences when compared to healthy controls \[[@CR15], [@CR16]\]. Given the inconsistency of previous reports, as well as lack of information on these T cells profile in the Ethiopian setting, the aim of this study was to assess the distribution of γδ T cells and their subsets Moreover, the expression of activation, adhesion and exhaustion markers was measured to further reveal the possible role these T cells play in such diseases.

Methods {#Sec2}
=======

Study setting and population {#Sec3}
----------------------------

This cross-sectional study, conducted between February 2015 to June 2016, involved a total of 52 participants recruited from a tertiary health facility, the anti-retroviral treatment (ART) follow up clinic of the All African Leprosy and Rehabilitation Training Center (ALERT Hospital), Addis Ababa and two additional medium sized health centers, Arada Health Center and Teklehaimanot Health Center in Addis Ababa.

Twenty two of the participants were HIV positive TB negative patients and 10 were HIV negative pulmonary TB patients. The HIV positive TB negative cases were all asymptomatic, free of any opportunistic infections and were on HAART for at least 2 years before inclusion into the study, whereas the HIV negative TB patients were treatment-naïve pulmonary TB patients, presenting with clinical TB signs and symptoms and confirmed with acid fast bacilli (AFB) smear microscopy. Additionally, 20 age and sex matched apparently healthy individuals were recruited as controls from Voluntary Counseling Testing centers (VCT). Healthy controls with acute illness, chronic disease conditions such as diabetes, hematological malignancies, HIV and lymphomas were excluded from the study. All participants gave written informed consent and the study received ethical approval from institutional review committee at the Department of Medical Laboratory Science, Addis Ababa University, AHRI/ALERT Ethics Review Committee and the Ethiopian National Research Ethics Review Committee.

Flowcytometry analysis {#Sec4}
----------------------

Multicolor flowcytometry was used to study the percentage of cells expressing activation, adhesion, exhaustion and memory markers on Vδ1 and Vδ2 T cell subsets in HIV + TB- and HIV-TB+ patients, and healthy controls. Typically, 8 ml of peripheral venous blood was collected from eligible participants in heparin tubes and dispensed and lysed in polystyrene Florescence Activated Cell Sorter (FACS) tubes using red blood cell (RBC) lysis buffer (0.15 M Ammonium chloride). Following lysis, leukocytes were washed with phosphate buffered saline (PBS), and resuspended in FACS buffer (1 mg/ml bovine serum albumin, 1 mM EDTA in PBS). Cells were subsequently stained for cell surface markers using fluorochrome conjugated monoclonal antibodies, namely Vδ2-PE, TCR γδ-PE, CD56-APC, CD8-APC-Cy7, CD38-V450, CD3-V500, CD95-V450, CD27-V500, CD45RA-PE-Cy7, all from Beckton Dickinson (BD Biosciences, Belgium), Vδ1-FITC (ThermoFisher, South Africa) and PD1-APC, CD103-PE-Cy7 (eBioscience,USA). Cells were incubated for 20 min at 4 °C, washed with FACS buffer and fixed with 2% paraformaldehyde. Data was acquired on a FACSCanto II flow cytometer using FACSDiva software (BD Biosciences). Analysis of lymphocyte sub-population frequencies and the relative expression of the different markers was performed with FlowJo Version 9.9.4 Software (TreeStar Inc., USA) after gating on CD3^+^ T lymphocyte subsets expressing markers for Vδ1^+^ and Vδ2^+^ (see Fig. [2](#Fig2){ref-type="fig"}).

IPP-specific IFN-γ response whole blood stimulation assay {#Sec5}
---------------------------------------------------------

For this experiment, 100 μl of heparinized whole blood was dispensed into 96 well plates (BIORAD, USA) in duplicate and was stimulated with or without 50 μM isopentenyl pyrophosphate (IPP) (Sigma Aldrich, USA) in RPMI 1640 medium supplemented with 10% Fetal Calf Serum, 1% L -glutamine, penicillin, and streptomycin. After 24 h incubation in 5% CO~2~ incubator at 37 °C, supernatants were harvested from each well for detection of IPP-specific IFN-γ production using an Enzyme Linked Immunosorbent Assay (ELISA) (BIORAD, USA).

The data obtained in the presence of stimuli exhibited Optical Density (OD values above unstimulated controls, but were low and in the non-linear portion of the IFN-γ standard curve. Considering the extrapolation of OD values to IFN-γ concentrations therefore unreliable, and since all culture supernatants were evaluated by ELISA in the same experiment, we opted to simply express data as OD units in the presence of stimulus less that in the absence of stimulus.

Statistical analysis {#Sec6}
--------------------

The data was entered into excel, cleaned and imported to Statistical Package for Social Sciences (SPSS) Software Version 21.0 (Chicago, IL, USA) for statistical analyses. Frequencies and proportions were used to describe the characteristics of study participants in relation to relevant variables. The non parametric, Mann-Whitney *U* test was used to compare median percentage of cell subsets among different study groups. Graphpad Prism Version 6.0 was used to generate graphs. A *p*-value \< 0.05 was considered as statistically significant.

Results {#Sec7}
=======

In this study 52 study subjects participated and were categorized in three groups based on their disease status. The three groups were similar with respect to age and sex. The mean age of the patients was 35.4 and 32.4 for HIV + TB- and HIV-TB+ groups, respectively (Table [1](#Tab1){ref-type="table"}).Table 1Socio-demographic characteristics of HIV + TB-, HIV-TB+ patients and healthy controlsStudy GroupsnSexAge in yearsMaleFemaleMean (SD)HIV + TB-2291335.4 (7.4)HIV-TB+105532.4 (11.5)Healthy controls2012831.2 (9.4)Total522626

Distribution of γδ T cells and their subsets in peripheral whole blood {#Sec8}
----------------------------------------------------------------------

The median percentage of total γδ T cells among CD3^+^ T lymphocytes was comparable in HIV + TB- subjects and healthy controls with respective medians of 3.7% and 3.5%. HIV-TB+ subjects exhibited a slightly higher median (5.3%) though this value did not reach statistical significance (Fig. [1](#Fig1){ref-type="fig"}). Further delineation into Vδ1 and Vδ2 subsets revealed that while Vδ1 percentages were higher in HIV + TB- than in HC subjects (*p* = 0.07, borderline significance), Vδ2 percentages were significantly lower. The percentages of total γδ T cells among HIV-TB+ subjects did not differ from HC (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Distribution of total and subsets of gamma-delta T cells. Distribution of total γδ (**a**), Vδ1 (**b**) and Vδ2 T cells (**c**). Data shown are box plots depicting median, intra-quartile range and range of subset frequencies defined from peripheral blood cells of 22 HIV + TB- and 10 HIV-TB+ patients, and 20 healthy controls. *p* values are from the Mann Whitney *U* Test

Expression of activation and other markers by Vδ1 and Vδ2 T cells subsets {#Sec9}
-------------------------------------------------------------------------

We next defined the expression of a range of other markers related to lineage, adhesion, activation, and exhaustion on the two γδ subsets using a gating strategy as defined in Fig. [2](#Fig2){ref-type="fig"}. Our results showed that the median percentage of Vδ1 T cells expressing CD8 did not significantly differ across all three study groups. However, expression of the activation marker CD38 among Vδ1 cells was significantly higher in both patient groups, HIV + TB- and HIV-TB+, compared to healthy controls (*p* \< 0.001). Similarly, the frequency of the adhesion marker CD103 in Vδ1 cells was significantly higher in both patient groups, HIV + TB- (*p* = 0.013) and HIV-TB+ (*p* = 0.005), compared to healthy controls. In addition, the expression of exhaustion markers CD95 and PD1 were significantly higher in both patient groups. In contrast, the frequency of CD56 among Vδ1 cells was significantly lower in the patient groups compared to healthy controls (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Gating of gamma delta T cells sub-populations and different markers. Gating strategy to define gamma delta T cells, sub-populations thereof, and different surface marker expression from one representative HIV patient. Single cells were gated from CD3+ lymphocytes. Vδ1 and Vδ2 T subsets were defined and these gated subsets were further evaluated for expression of different surface markers. Thresholds to define indistinct markers such as CD38 on γδ T cells were copied from that defined on αβ T cells as depicted in the figureFig. 3Expression of different biomarkers on Vδ1 subsets. Median percentage of CD8 (**a**), CD56 (**b**), CD38 (**c**), CD103 (**d**), CD95 (**e**), and PD1 (**f**) on Vδ1 T cell subsets from peripheral blood cells of 22 HIV + TB-, 10 HIV-TB+ patients and 20 healthy controls. *p* values are from the Mann Whitney *U* Test

Similar to our findings of Vδ1 T cells, the median percentage of CD38 expressing cells within the Vδ2 subset was significantly higher in the two patient groups than healthy controls (*p* \< 0.001), as shown in Fig. [4](#Fig4){ref-type="fig"}. The frequency of cells positive for the exhaustion markers CD95 and PD1 among Vδ2 T cells were similarly higher in patients compared to healthy controls (*p* = 0.001). HIV negative TB patients had significantly higher proportions of Vδ2 T cells (*p* = 0.002) and PD1 expressing Vδ2 cells (*p* = 0.013) compared to HIV positive TB negative patients.Fig. 4Expression of different biomarkers on Vδ2 subsets. Median percentage expression of CD38 (**a**), CD95 (**b**) and PD1 (**c**) on Vδ2 T cell subsets from peripheral blood cells of 22 HIV + TB-, 10 HIV-TB+ patients and 20 healthy controls. *p* values are from the Mann Whitney *U* Test

Expression of differentiation markers by Vδ2 T cells subsets {#Sec10}
------------------------------------------------------------

The Vδ2 T cells subsets were further gated and analyzed for the expression of CD27 and CD45RA markers as defined in Fig. [5](#Fig5){ref-type="fig"} to determine the frequency of naïve, memory and effector phenotypes.Fig. 5Gating of memory markers on conventional T cells and gamma delta T cells. Frequency of Vδ2 cells stained with CD27 and CD45RA mAbs. Peripheral blood cells from 22 HIV patients, 10 pulmonary TB patients and 20 controls were stained. Left panel (**a**) shows a representative pseudo-color plot of CD27 versus CD45RA staining among Vδ2 T cells and αβ T cells from one HIV patient. Right panel (**b**) depicts bivariate staining of CD27 and CD45RA among Vδ2 T cell and αβ T cells from one representative healthy control. Notably, as shown in the figure (Fig. 5), thresholds discriminating subsets on the basis of CD27 and CD45RA were defined on αβ T cells and copied to plots expressing these markers on gated Vδ2 T cells

The median frequency of central memory (CD45RA-CD27+) Vδ2 T cells subsets was significantly higher in healthy controls compared to HIV + TB- (*p* \< 0.001) and HIV-TB+ (*p* = 0.02) patients. Though not significant, the frequency of naïve (CD45RA + CD27+) Vδ2 T cells was higher in the healthy controls. In contrast, the median frequency of effector cytotoxic (CD45RA + CD27-) Vδ2 T cells was significantly higher in both patient groups compared to healthy controls (*p* = 0.001). However, we did not find significant differences in the frequency of intermediate effector/effector memory (CD45RA-CD27-) Vδ2 T cells between HIV positive patients and controls. In addition, a higher proportion of these cells was observed in HIV negative pulmonary TB patients (*p* = 0.034) than healthy controls (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Expression of differentiation markers on Vδ2 subsets. Expression of differentiation markers on Vδ2 T cell naïve (**a**), central memory (**b**), effector cytotoxic (**c**), and effector memory (**d**) subsets from peripheral blood of 22 HIV + TB-, 10 HIV-TB+ patients and 20 healthy controls. *p* values are from the Mann Whitney *U* Test

Functional response of Vδ2 T cells {#Sec11}
----------------------------------

The cytokine functional response of Vδ2 T cells was evaluated by measuring the level of IFN-γ production following overnight stimulation with IPP. HIV + TB- patients had the lowest IFN-γ OD level compared to healthy controls and HIV-TB+ patients; no significant difference was observed between HIV-TB+ patients and controls (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7IFN-γ response by Vδ2 T subsets to Isopentenyl Pyrophosphate stimulation. Comparison of median IFN-γ responses by Vδ2 T cells after stimulating with 50 μM IPP for 24 h in 22 HIV + TB-, 10 HIV-TB+ patients and 20 healthy controls. IFN-γ response is depicted as optical density (OD) of the supernatant, as described in materials and methods. *p-*value is from the Mann-Whitney *U* test

Discussion {#Sec12}
==========

The distribution of total γδ T cells, and Vδ1 and Vδ2 subsets was analyzed in the peripheral blood of HIV and pulmonary TB patients and compared with values from apparently healthy individuals. We also analyzed the expression of activation and adhesion markers on Vδ1 T cells, and exhaustion and differentiation markers and phosphoantigen-specific IFN-γ responses of Vδ2 cells. The median percentage of total γδ T cells was similar between the patients and healthy controls which is in agreement with previous reports \[[@CR8], [@CR9]\].

The current study demonstrated an increased proportion of Vδ1 cells in HIV + TB- patients, though of statistically marginally significance compared to controls. Similar results were reported in previous studies, but with greater statistical significance \[[@CR17], [@CR18]\]. On the other hand the frequency of Vδ2 cells was significantly lower in HIV + TB- patients compared to healthy controls and HIV-TB+ patients in the current study, such observation was also reported by previous findings \[[@CR9], [@CR17]\].

There is no clear consensus with regard to the distribution of Vδ2 T cells in HIV negative pulmonary TB patients and healthy controls. Li et al. \[[@CR19]\] showed significantly lower Vδ2 T cells number in pulmonary TB patients compared to controls, Carvalho et al. also reported significantly lower values of these T cells in pulmonary TB patients irrespective of their HIV status \[[@CR20]\]. In contrast, there are reports describing increased proportion of Vδ2 T cell subsets in pulmonary TB patients co-infected with HIV \[[@CR21]\]. Other studies found no difference in these T cells distribution between pulmonary TB patients and healthy controls \[[@CR16]\], similar to our findings in this study. Possibly, the lack of observed consistency in the distribution of Vδ2 T cells in pulmonary TB patients may be related to study dependent differences in the stage of TB disease, or differences in Purified Protein Derivative (PPD) reactivity. Of note, one study showed PPD negative patients had higher counts of γ/δ T cells than those PPD positive patients or controls \[[@CR15]\]. Other studies, however, have shown that the distribution of these cells and their subsets was not associated with response to PPD \[[@CR20]\]. Other possibly variables contributing to differences between studies include age; some studies enrolled more of adults \[[@CR15], [@CR20]\] while other included younger children \[[@CR16]\]. The study sample size may contribute as well; we enrolled only limited numbers of pulmonary TB patients, whereas other studies enrolled more subjects \[[@CR15], [@CR20]\].

Significantly higher proportions of Vδ1 T cells expressed the activation marker CD38 and adhesion marker CD103 in HIV + TB- patients in this study, consistent with previous reports \[[@CR7], [@CR9]\]. This finding is compatible with the involvement of inflammation and stress induced molecules such as MHC class I polypeptide-related sequence A and B (MICA and MICB) known to stimulate these cells and influence their mucosal attachment \[[@CR2]\]. In vitro studies demonstrated that HIV can breach the mucosal barrier and facilitate the translocation of viruses and bacteria \[[@CR22]\], potentially contributing to local immune reactivity and promoting emigration of these T cell subsets into the peripheral blood, possibly through modulation of some chemokine ligands \[[@CR23]\]. Supporting this possibility, a recent study revealed an elevated level of a microbial translocation marker sCD14, which was associated with γδ T cells activation and this activation increased over time \[[@CR24]\]. The repertoire analysis of CDR3 length polymorphisms among peripheral and mucosal Vδ1 T cells is an approach which can reveal close lineage relationship of these cells and support the hypothesis of a mucosal activated source of circulating blood Vδ1 cells. Poles et al. study, however, indicated that despite having increased expression of mucosal homing receptors such as CD103 and CCR9 on γδ T cells, the repertoires from peripheral blood and mucosal area appeared to represent two distinct populations in HIV patients \[[@CR9]\]. Moreover, in our current study the Vδ1 subset also exhibited significant expression of exhaustion markers CD95 and PD1 in HIV patients suggesting persistent activation of these cells and possibly to altered function. Chronic HIV is associated with reduced effector function of mucosal Vδ1 and Vδ2 T-cells \[[@CR25]\].

Despite being asymptomatic and on long term HAART, the current research showed that HIV patients have significantly lower percentages of the Vδ2 subset as well as reduced IFNγ production in response to phosphoantigen (IPP) stimulation, a finding observed in other studies \[[@CR26], [@CR27]\]. One possible mechanism for reduced numbers and function of these cells could be direct infection and destruction by HIV-1 itself, at least among those Vδ2 expressing CD4 and chemokine receptors CCR5 and CXCR4 \[[@CR28]\] or α4β7 \[[@CR29]\]. Of note, increased expression of α4β7 and CCR5 at the surface of activated Vδ2 T cells at close proximity has been found to promote the binding of HIV envelope glycoprotein, which ultimately causes significant killing of these subsets \[[@CR29]\]. Additional mechanisms are suggested by our observation of significantly higher expression of CD38, CD95 and PD1 on Vδ2 cells which may reflect an on-going exhaustion or initiation of fas-mediated activation induced cell death. These mechanisms are well described to contribute to loss and/or dysfunction of conventional α/β CD4 and CD8 T cells in HIV patients, and have support in studies of γ/δ T cells \[[@CR30], [@CR31]\].

As demonstrated by previous reports \[[@CR30]\] and in the current study, the compartmentalization of Vδ2 T cells to subsets of naïve and memory cells according to the expression of markers such as CD45RA and CD27 is not as clear compared with that of conventional α/β T cells. Using gating defined on α/β T cells, we defined Vδ2 T cell subsets as naïve (CD45RA + CD27+), central memory (CD45RA- CD27+), effector memory (CD45RA-CD27-), and effector cytotoxic (CD45RA + CD27-) cells \[[@CR32]\]. Previous studies showed HIV patients \[[@CR30]\] and pulmonary TB patients \[[@CR33]\] had significantly reduced numbers of Vδ2 T cells with the CD45RA-CD27- (effector memory) phenotype. However, in the current and another study \[[@CR25]\] there was no significant difference in expression of the effector memory phenotype between HIV patients and healthy controls, and a higher proportion in pulmonary TB patients compared with controls. The overexpression of effector memory cells that we observed in TB patients is particularly relevant in light of observations that Vδ2 cells with the effector memory and effector cytotoxic phenotype expressed relatively abundant IFN-γ \[[@CR33]\] and Granzyme B /perforin \[[@CR32]\]. Future studies with more detailed functional characterization of Vδ2 subsets in TB patients may therefore shed light into their role as an important component of the host response to TB.

Conclusion {#Sec13}
==========

The current study indicated that the frequency of total γδ T cells was similar among HIV and pulmonary TB patient groups and healthy controls. HIV infection was associated with an increase in the Vδ1 subset and a decrease in the Vδ2 subset frequency and function. Patients with HIV and pulmonary TB infections exhibited significantly higher expression of activation, adhesion and exhaustion markers on Vδ1 T and Vδ2 T cell subsets. HIV negative pulmonary TB patients had significantly higher proportions of effector Vδ2 T cells, consistent with an active role these T cells play in mycobacterial defense and/or pathogenesis. This study is the first of its kind in this country which assessed the distribution of these T cells. However, further longitudinal studies evaluating phenotypic and functional properties of γδ T cells in patients before and after therapy, as well as the inclusion of co-infected patients and larger sample size may help to resolve underlying etiologies contributing to altered distributions of γδ T lymphocytes and their role in the pathogenesis of the diseases in these patients.
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